Time Restricted Eating for Breast Cancer Survivors
(TEST2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how time-restricted eating affects brain function in older women who survived early-stage breast cancer and completed chemotherapy at least a year ago. Researchers examine how lifestyle habits and health markers, such as blood sugar and cholesterol, influence memory and thinking skills. Participants will either follow a time-restricted eating schedule or receive healthy eating education without altering meal timing. Women aged 60-85 who completed chemotherapy for early-stage breast cancer over a year ago and have a BMI of 25 or higher may be suitable candidates. As an unphased study, this trial allows participants to contribute to valuable research on lifestyle changes that may enhance cognitive health.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that time-restricted eating (TRE) is safe and well-tolerated for breast cancer survivors. In one study, participants who ate only during an 8-hour window each day for eight weeks found it manageable and safe after finishing chemotherapy. Another study found that this method helped lower the risk of heart problems in older survivors who were overweight or at risk for heart disease. These findings suggest that TRE can be a safe way to manage health after cancer treatment.12345
Why are researchers excited about this trial?
Researchers are excited about time-restricted eating (TRE) for breast cancer survivors because it offers a non-invasive, lifestyle-based approach to improving health outcomes. Unlike traditional treatments that might focus on medications or surgery, TRE simply involves limiting food intake to an 8-hour window each day, potentially leading to better metabolic health and weight management without the side effects of pharmaceuticals. Additionally, TRE could enhance the body's natural rhythms and improve sleep quality, which are crucial for recovery and overall well-being. This approach is particularly appealing because it empowers individuals to make dietary changes that fit their personal schedules, offering flexibility and potentially improving adherence to healthier habits.
What evidence suggests that time restricted eating might be an effective treatment for brain function decline in breast cancer survivors?
Research has shown that time-restricted eating (TRE), which participants in this trial may follow, might benefit breast cancer survivors. Women who fasted for less than 13 hours each night had a higher chance of breast cancer recurrence. Studies also suggest that TRE could reduce metabolic problems, potentially lowering overall cancer risks. Animal studies found that fasting might enhance chemotherapy effectiveness and reduce its side effects. Additionally, TRE could decrease the risk of heart disease, which is crucial for older breast cancer survivors. Overall, early evidence suggests that TRE might support better health and help protect brain function.34567
Who Is on the Research Team?
Amy A Kirkham, PhD
Principal Investigator
University of Toronto
Are You a Good Fit for This Trial?
This trial is for female breast cancer survivors aged 60-85 who completed chemotherapy at least a year ago. It aims to understand how lifestyle habits and health markers influence brain function after treatment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Comprehensive assessment including cognitive and physical function tests, and distribution of study materials
Treatment
Participants are randomly allocated to either time restricted eating with protein counselling or healthy eating education for 16 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with a final assessment at 40 weeks
What Are the Treatments Tested in This Trial?
Interventions
- Time Restricted Eating
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Toronto
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator